The FY2025 (Dec) proxy of Agios Pharmaceuticals names 14 peer companies for pay. Among Agios Pharmaceuticals and these peers, CEO pay was the lowest of 3 and total shareholder return was 2nd highest of 3.
3rd highest of 3in Agios Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
2nd highest of 3in Agios Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
Pay peer group, FY2025 (Dec) proxy
| Ultragenyx Pharmaceutical | ||
| Mirum Pharmaceuticals | ||
| Acadia Pharmaceuticals | Not disclosed | Not disclosed |
| Amicus Therapeutics, Inc. | Not disclosed | Not disclosed |
| Apellis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Arcus Biosciences, Inc. | Not disclosed | Not disclosed |
| Biocryst Pharmaceuticals | Not disclosed | Not disclosed |
| Blueprint Medicines Corporation | Not disclosed | Not disclosed |
| Crinetics Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Intellia Therapeutics, Inc. | Not disclosed | Not disclosed |
| Rhythm Pharmaceuticals | Not disclosed | Not disclosed |
| Sage Therapeutics, Inc. | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
| Travere Therapeutics, Inc. | Not disclosed | Not disclosed |
PSU comparator group
The companies that relative total shareholder return is measured against for performance stock units.
| NASDAQ Biotechnology Index (index) | Not disclosed | Not disclosed |
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.